Sign in
Not yet recruitingNo phase

Closed-loop TMS for the Core Clinical Features of Methamphetamine Use Disorder

Key facts

Who runs it
Shanghai Mental Health Center
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
21 people, planned
Started
Oct 2026
Expected to end
Dec 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Closed-loop TMS
  • Conventional TMS
  • Random TMS
Record updated
2 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Aged 18 years old or older, with at least 9 years of education (junior high school or above) or able to fully understand the task
  • Meets Meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) for mild/severe amphetamine-type substance use disorder
  • History of amphetamine-type substance use for no less than 1 year, with use at least once per week

Who cannot take part

  • Presence of any organic disease, or diagnosis of any other psychiatric disorder according to DSM-5 (e.g., bipolar disorder, major depression disorder)
  • Contraindications to TMS, as assessed by the Transcranial Magnetic Stimulation Adult Safety Screen (TASS)
  • Inability to complete assessments, treatment procedures, or follow-up due to cognitive or behavioral limitations

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate whether closed-loop transcranial magnetic stimulation (TMS) targeting left-dorsolateral prefrontal cortex (l-DLPFC) can improve core clinical symptoms in individuals with methamphetamine use disorder (MUD), such as cue-reactivity and impaired inhibitory control.

Read full original descriptionShow less

The main questions it aims to answer are:

Can closed-loop TMS targeting l-DLPFC significantly reduce cue-reactivity, as measured by a Visual Analog Scale (VAS) and cue-reactivity task, compared to a conventional treatment protocol and random TMS ? Does closed-loop stimulation targeting l-DLPFC enhance cognitive control, assessed by performance on the Stop Signal Task (SST), more effectively than the other stimulation modes? Researchers will compare closed-loop, conventional, and random TMS conditions targeting l-DLPFC to determine whether closed-loop yields superior symptom improvement.

Participants will:

Be randomly assigned to one of the three stimulation groups (closed-loop, conventional and random) according to a pre-generated random number table, and receive the corresponding stimulation session targeting l-DLPFC.

Undergo cue-reactivity assessment using VAS and cue-reactivity task, and complete the SST before and after each stimulation session.

The 3 groups in the trial

  • Closed-loop GroupTreatment being tested

    Participants in this arm will receive closed-loop TMS. Before stimulation: The researchers measure the participant's Resting Motor Threshold (RMT) and assess their craving using VAS before and after viewing a methamphetamine-related video. The participants complete SST. During the stimulation phase, participants will: First undergo a training phase, during which EEG is recorded while they perform a cue-reactivity task to identify neural signatures and calculate stimulation thresholds. Then perform the cue-reactivity task again, and real-time EEG features are used to trigger TMS in a closed-loop mode, targeting l-DLPFC. After the stimulation, participants will: The researchers again assess their craving using VAS before and after viewing the video. The participants again complete the SST. The researchers record adverse reactions and adverse events, and evaluate the blinding effect, through a Blinding Assessment Questionnaire.

    Treatment: Closed-loop TMS

  • Conventional TMS GroupExisting treatment, for comparison

    Participants in this arm will receive conventional TMS. Before stimulation: The researchers measure the participant's RMT and assess their craving using VAS before and after viewing a methamphetamine-related video. The participants complete SST. During the stimulation phase, participants will: First undergo a training phase, during which EEG is recorded while they perform a cue-reactivity task to identify neural signatures and calculate stimulation thresholds. Then receive a TMS treatment delivered at a conventional iTBS protocol, targeting l-DLPFC, and perform the cue-reactivity task again afterwards. After the stimulation, participants will: The researchers again assess their craving using VAS before and after viewing a methamphetamine-related video. The participants again complete the SST. The researchers record adverse reactions and adverse events, and evaluate the blinding effect, through a Blinding Assessment Questionnaire.

    Treatment: Conventional TMS

  • Random GroupExisting treatment, for comparison

    Participants in this arm will receive random TMS. Before stimulation: The researchers measure the participant's Resting Motor Threshold (RMT) and assess their craving using VAS before and after viewing a methamphetamine-related video. The participants complete SST. During the stimulation phase, participants will: First undergo a training phase, during which EEG is recorded while they perform a cue-reactivity task to identify neural signatures and calculate stimulation thresholds. Then perform the cue-reactivity task again, and TMS is triggered by a random sequence unrelated to real-time EEG features, targeting l-DLPFC. After the stimulation, participants will: The researchers again assess their craving using VAS before and after viewing a methamphetamine-related video. The participants again complete the SST. The researchers record adverse reactions and adverse events, and evaluate the blinding effect, through a Blinding Assessment Questionnaire.

    Treatment: Random TMS

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Single-blind, Randomized, Parallel Study of Closed-loop, Conventional and Random TMS for Core Clinical Features of Methamphetamine Use Disorder.
Record updated
2 November 2026